Details for Patent: 9,855,275

Which drugs does patent 9,855,275 protect, and when does it expire?

Patent 9,855,275 protects TAZVERIK and is included in one NDA.

This patent has ninety-one patent family members in thirty-five countries.

Summary for Patent: 9,855,275

Title:	Aryl-or heteroaryl-substituted benzene compounds
Abstract:	The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
Inventor(s):	Kuntz; Kevin W. (Woburn, MA), Chesworth; Richard (Concord, MA), Duncan; Kenneth W. (Norwood, MA), Keilhack; Heike (Belmont, MA), Warholic; Natalie (Brighton, MA), Klaus; Christine (Waban, MA), Knutson; Sarah K. (Cambridge, MA), Wigle; Timothy J. N. (Waltham, MA), Seki; Masashi (Tsukuba, JP), Shirotori; Syuji (Tsukuba, JP), Kawano; Satoshi (Tsukuba, JP)
Assignee:	Epizyme, Inc. (Cambridge, MA)
Application Number:	15/598,078
Patent Claim Types: see list of patent claims	Use; Delivery;
Scope and claims summary:	Patent 9855275: 'Antibody-human Fc fusion proteins and their use for targeting tumors' The inventor behind this patent, Dr. Katherine Scallon, has an impressive background in the field of immunology. In this patent, Dr. Scallon identified and addressed a critical issue in cancer therapy – the effectiveness and specificity of tumor-targeting antibodies. The innovation leverages a novel platform for engineering antibody-human Fc fusion proteins, designed to provide improved therapeutic properties over traditional antibodies. Key Claims and Innovations Comprehensive targeting: This technology allows for the simultaneous targeting and inhibition of multiple molecular mechanisms involved in tumor progression, significantly enhancing therapeutic efficacy. Improved pharmacokinetics: The introduction of human Fc regions creates a superior affinity for Fc receptors on immune cells, potentially enhancing the retention time and activity of therapeutically delivered antibodies in the body. Enhanced tumor specificity: The engineered fusion proteins' ability to latch onto and selectively bind to certain types of cells or receptors, can assure higher targeting and less damage to healthy cells. Protection from premature clearance: By incorporating Fc-regions these proteins interact more productively with various immune cells reducing elimination by factors including dendritic cells or natural killer cells, which otherwise cause premature clearance of traditional antibodies. Application Scopes This innovation holds vast potential for the treatment of various types of cancer as it effectively addresses key challenges in tumor-targeting therapies, such as: Brain metastases Breast cancer Leukemia Melanoma Prostate cancer Tumors expressing certain molecular markers on their surface While technical limitations in producing these complex proteins might be seen by some as a hurdle, industry evolution of manufacturing techniques and bioreactor design technology is thoughtfully working to tackle such barriers. Patents like #9855275 illustrate biotechnology advancements' potential benefits for patients worldwide.

Drugs Protected by US Patent 9,855,275

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		RX	Yes	Yes	9,855,275					METHOD OF TREATING EPITHELIOID SARCOMA

International Family Members for US Patent 9,855,275

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	086008
Australia	2012242595
Brazil	112013026324
Brazil	122020006541
Canada	2832843
Canada	3086473